Clinical Trial Update: A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects [Phase 2]

View source ↗

Summary

The Phase 2 clinical trial evaluating Nexagon for persistent epithelial defect has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Epithelial Defect

Drugs mentioned

• NEXAGON

Snippet

Sponsor: OcuNexus Therapeutics, Inc. | Conditions: Persistent Epithelial Defect | Phase 2 | Status: WITHDRAWN